Alto Neuroscience, Inc. Cash and Restricted Cash
Alto Neuroscience, Inc. (ANRO) had Cash and Restricted Cash of $244.23 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $244.23M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $264.26M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $176.98M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $138.32M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $244.23M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $264.26M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $176.98M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $138.32M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $148.09M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $161.25M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $168.73M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $182.20M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $193.62M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $205.90M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $82.55M 10-K · filed 2026-03-16 |
| 2023-09-30 | $51.29M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $59.03M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $65.78M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $48.34M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |